Our studies provide insight into mechanisms modulating DNA damage-induced apoptosis and may help to develop more effective treatment for TRAF2 or TRAF3 mutant B-cell lymphomas using IAP antagonists. This evidence concerns the gene TRAF3 and B-cell non-Hodgkin lymphoma.